RHAPSIDO
GrowthNDAORALTABLETPriority Review
Approved
Sep 2025
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 26m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RHAPSIDO (remibrutinib) is an oral Bruton's Tyrosine Kinase (BTK) inhibitor small molecule approved by FDA on September 30, 2025. It selectively targets BTK to modulate B-cell and myeloid cell signaling, with applications across hematologic and autoimmune conditions. The drug represents Novartis's entry into the competitive BTK inhibitor class with a novel mechanism designed for improved selectivity and tolerability.
Launch16.2 years to LOE
As a newly launched product, the brand team is in build-out phase with aggressive market development and sales force expansion planned through 2026-2027.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RHAPSIDO launch roles are high-impact and immediately available across Novartis commercial and medical organizations. Joining at launch offers rapid career acceleration in brand building, field-based selling, and market access strategy within the high-growth kinase inhibitor category.
Brand ManagerMedical Science Liaison (MSL)
Worked on RHAPSIDO at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.